SNDX Stock Price
Syndax Pharmaceuticals, Inc.
SNDX stock price is $16.90 (-0.76% on the day), giving Syndax Pharmaceuticals, Inc. a market cap of $1.51B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
SNDX Stock Overview
- Price
- $16.90
- Previous close
- $17.03
- Open
- $16.90
- Market cap
- $1.51B
- P/E ratio
- -5.3
- 52-week range
- $12.99 - $25.59
- 1-year price target
- $37.25
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 28
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are Revuforj, a menin inhibitor, which has completed phase 2 clinical trial for the treatment of relapsed or refractory and acute leukemia. The company is revumenib for R/R mNPM1 AML and studying the use of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia across the treatment landscape, including in newly diagnosed patients. It also developing Niktimvo, a colony stimulating factor-1 receptor, blocking antibody, which is in phase 2 clinical trial for the treatment of chronic graft-versus-host disease. The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SNDX | $16.90 | -0.8% | 2.14M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Syndax Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW